https://mybinxhealth.com/news/binx-health-collaborates-with-amazon-business-for-delivery-of-covid-19-sample-collection-kits-to-u-s-businesses-schools-and-governments/
Green light by the AEMPS to start clinical trials with OMO-103
http://www.peptomyc.com/green-light-by-the-aemps-to-start-clinical-trials-with-omo-103/
Veteran Healthcare Leader David P. King Joins binx health Board of Directors
-Former LabCorp Chairman and CEO joins binx board during period of rapid growth- BOSTON, MA, [DATE]– binx health today announced the addition of David P. King to its Board of Directors. Mr. King served for nearly 13 years as Chairman and CEO of LabCorp, where he spearheaded the company’s transformation from a pure-play clinical laboratory into a global leader in life sciences, tripling the size of the company to more…
ONA Therapeutics appoints Mark Throsby to its Board of Directors
Barcelona, Spain, March 5th, 2021: Ona Therapeutics, a company focused on the discovery and development of therapeutic biologics to treat metastatic cancer, announces today that it has appointed Dr. Mark Throsby as independent board member of its Board of Directors. Dr. Throsby is a proven senior executive with more than 20 years of experience in the pharma & biotech industry and has led multiple drug discovery programs from conception to…
Accure Therapeutics enrols first patient in phase II clinical trial on acute optic neuritis with lead candidate ACT-01
https://accure.health/accure-therapeutics-enrols-first-patient-in-phase-ii-clinical-trial-on-acute-optic-neuritis-with-lead-candidate-act-01/
Alta Life Sciences participa en el grupo de trabajo de AseBio para impulsar el sector biotech
https://www.asebio.com/actualidad/noticias/asebio-une-las-principales-gestoras-especializadas-de-capital-riesgo-para
binx health Enters into Distribution Agreement for National Launch of the FDA-cleared binx io
https://mybinxhealth.com/news/binx-health-enters-into-distribution-agreement-for-national-launch-of-the-fda-cleared-binx-io/
Accure Therapeutics publishes pivotal preclinical efficacy study in epilepsy
https://accure.health/accure-therapeutics-publishes-pivotal-preclinical-efficacy-study-in-epilepsy/
Sanifit Granted Orphan Drug Designation by the FDA for SNF472 for the Treatment of Peripheral Arterial Disease in Patients with End-stage Kidney Disease
https://www.sanifit.com/sanifit-granted-orphan-drug-designation-by-the-fda-for-snf472-for-the-treatment-of-peripheral-arterial-disease-in-patients-with-end-stage-kidney-disease/
Accure Therapeutics – Webinars on Neuroprotection for Brain Diseases Program
https://accure.health/webinars-on-neuroprotection-for-brain-diseases-program/